RAPT Therapeutics, Inc.

DB:0RA0 Stock Report

Market Cap: €424.6m

RAPT Therapeutics Valuation

Is 0RA0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RA0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0RA0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0RA0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RA0?

Key metric: As 0RA0 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0RA0. This is calculated by dividing 0RA0's market cap by their current book value.
What is 0RA0's PB Ratio?
PB Ratio3x
BookUS$164.41m
Market CapUS$498.45m

Price to Book Ratio vs Peers

How does 0RA0's PB Ratio compare to its peers?

The above table shows the PB ratio for 0RA0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average10x
7ZT Hamlet BioPharma
25.4xn/a€938.1m
HPHA Heidelberg Pharma
7.8x-11.43%€144.9m
FYB Formycon
1.1x97.68%€447.8m
LQ0 Dextech Medical
5.9xn/a€158.1m
0RA0 RAPT Therapeutics
3x-28.03%€498.4m

Price-To-Book vs Peers: 0RA0 is good value based on its Price-To-Book Ratio (3x) compared to the peer average (10x).

Price to Book Ratio vs Industry

How does 0RA0's PB Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
MDG1 Medigene
0.1x14.15%US$2.07m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
0RA0 3.0xIndustry Avg. 3.1xNo. of Companies6PB00.61.21.82.43+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0RA0 is good value based on its Price-To-Book Ratio (3x) compared to the European Biotechs industry average (3.1x).

Price to Book Ratio vs Fair Ratio

What is 0RA0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RA0 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0RA0's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RA0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€24.87
0%
30.97%€32.37€11.07n/a5
Sep ’26€9.50
€19.13
+101.40%
46.51%€32.55€7.71n/a6
Aug ’26€8.95
€21.01
+134.72%
55.22%€42.01€7.00n/a6
Jul ’26€6.49
€26.09
+301.97%
60.74%€41.74€6.96n/a4
Jun ’26€6.24
€26.58
+326.01%
60.74%€42.53€7.09n/a4
May ’26€6.24
€36.72
+488.40%
66.33%€73.43€14.69n/a4
Apr ’26€9.12
€36.72
+302.59%
66.33%€73.43€14.69n/a4
Mar ’26€8.40
€46.13
+449.14%
54.43%€76.88€15.38n/a3
Feb ’26€8.80
€46.58
+429.31%
54.43%€77.63€15.53n/a3
Jan ’26€12.64
€46.06
+264.41%
54.43%€76.77€15.35n/a3
Dec ’25n/a
€18.90
0%
34.64%€30.24€15.12n/a4
Nov ’25€16.48
€57.72
+250.25%
59.95%€122.66€14.43n/a6
Oct ’25€14.16
€57.72
+307.64%
59.95%€122.66€14.43n/a6
Sep ’25€15.44
€67.74
+338.72%
42.71%€123.38€29.03€9.506
Aug ’25€23.04
€109.22
+374.05%
68.80%€242.99€29.45€8.956
Jul ’25€22.40
€109.39
+388.33%
68.80%€243.36€29.50€6.496
Jun ’25€29.28
€109.39
+273.59%
68.80%€243.36€29.50€6.246
May ’25€58.00
€162.11
+179.51%
55.96%€353.70€73.69€6.249
Apr ’25€64.00
€162.57
+154.02%
55.96%€354.70€73.90€9.129
Mar ’25€63.60
€163.84
+157.61%
54.74%€353.89€73.73€8.409
Feb ’25€180.80
€308.96
+70.88%
19.15%€445.54€226.42€8.8010
Jan ’25n/a
€310.41
0%
19.15%€447.64€227.49€12.6410
Dec ’24n/a
€305.38
0%
19.46%€448.37€227.86n/a11
Nov ’24€86.40
€314.97
+264.54%
19.73%€461.11€234.34€16.4812
Oct ’24€121.60
€315.60
+159.54%
19.73%€462.04€234.81€14.1612
€11.43
Fair Value
3.2% overvalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/05 18:50
End of Day Share Price 2025/09/11 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

RAPT Therapeutics, Inc. is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leiyang WangBarclays
Gao Yi ChenBerenberg
Guyn KimBMO Capital Markets Equity Research